Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments and has entered into a strategic agreement with Eli Lilly. Radionetics is advancing a pipeline of first-in-class small molecule radioligands targeting G protein coupled receptors for the treatment of a broad range of cancers, including breast cancer, lung cancer, and other indications of high unmet need.
Company Details
- Employees
- 42
- Founded
- -
- Address
- San Diego, Ca 92121, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://radionetics.com/
- Keywords
- jobs.
- HQ
- San Diego, CA
Radionetics Oncology Questions
Radionetics Oncology's website is https://radionetics.com/
Radionetics Oncology's LinkedIn profile is https://www.linkedin.com/company/radionetics-oncology
Radionetics Oncology has
42 employees.
View email and phone details for 42
employees at Radionetics Oncology.
Radionetics Oncology's industry is
Pharmaceutical Manufacturing
Radionetics Oncology's top competitors are
Proquality Network,
Medicines360,
Perceive Biotherapeutics, Inc.,
Concuir Consulting,
Boiron Laboratories,
Xseer Pharmaceuticals,
Aerogen Pharma,
Mcguff Companies,
Ashvattha Therapeutics, Inc.,
Spyglass Pharma, Inc..
Radionetics Oncology's categories are Pharmaceutical Manufacturing
Radionetics Oncology's founding year is 2021
